It is still very early days, but GSK’s respiratory syncytial virus (RSV) Arexvy seems to ... “outstanding”, is already talking about the vaccine’s potential to become a blockbuster product ...

The FDA has started its review of Pfizer’s respiratory syncytial virus (RSV) vaccine for older adults, fast-tracking the biologics license application (BLA) with a decision due in May 2023.

The FDA has accepted AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo's Biologics License Application for priority review for their drug datopotamab deruxtecan, also known as Dato-DXd, for the ...

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) gave its thumbs-up to eight new medicines including two vaccines ... and Daiichii Sankyo’s antibody-drug ...

Analysts expressed concerns about R&D spending, vaccine sales uncertainties ... s growth to offset Datroway’s shortfall. Daiichi Sankyo’s Q3 FY2024 results reflect strong performance in ...